Search

Your search keyword '"Mycophenolate sodium"' showing total 15 results

Search Constraints

Start Over You searched for: Descriptor "Mycophenolate sodium" Remove constraint Descriptor: "Mycophenolate sodium" Journal transplantation journal Remove constraint Journal: transplantation journal
15 results on '"Mycophenolate sodium"'

Search Results

1. Towards a Gold Standard for Adherence Assessment in Transplantation: High Accuracy of the Proteus Raisin System (PRS) Combined with Enteric-Coated Mycophenolate Sodium (ECMPS) in Stable Kidney Transplant Recipients

2. Improved Renal Function of an Everolimus/Enteric-Coated Mycophenolate Sodium Regimen after Calcineurin Inhibitor Withdrawal in de Novo Renal Transplant Patients: 4 Years Follow-Up of the ZEUS Trial

3. Everolimus Treated Renal Transplant Patients Develop a More Robust CMV-Specific CD8 Response Compared to Cyclosporine or Mycophenolate Sodium Treated Patients

4. Limited Sampling Strategy to Determine the Degree of Exposure to Mycophenolic Acid after Enteric- Coated Mycophenolate Sodium in Renal Transplant Adult Patients

5. EVEROLIMUS(E) VS ENTERIC COATED MYCOPHENOLATE SODIUM (EC-MPS): PROTEOMIC AND PATHOLOGIC ASPECTS IN A 1-YEAR PROSPECTIVE RANDOMIZED STUDY

6. INITIALLY INTENSIFIED DOSING REGIMEN OF ENTERIC-COATED MYCOPHENOLATE SODIUM (EC-MPS) OFFERS EARLY ADEQUATE MYCOPHENOLIC ACID (MPA) EXPOSURE IN DE NOVO RENAL TRANSPLANT RECIPIENTS

7. INITIAL INTENSIFIED DOSING OF ENTERIC-COATED MYCOPHENOLATE SODIUM (EC-MPS) VERSUS STANDARD DOSING IMPROVES REJECTION PROPHYLAXIS IN DE NOVO RENAL TRANSPLANT RECIPIENTS

8. A PROSPECTIVE MULTICENTER OPEN-LABEL RANDOMIZED STUDY TO ASSESS EFFICACY AND SAFETY OF EVEROLIMUS WITH CICLOSPORINE-MICROEMULSION (CSA-ME) VERSUS EVEROLIMUS WITHOUT CALCINEURINE INHIBITOR WITH MYCOPHENOLATE SODIUM, IN MAINTENANCE ADULT KIDNEY TRANSPLANT PATIENTS: FOREVER STUDY

9. POPULATION PHARMACOKINETICS OF MYCOPHENOLIC ACID: A COMPARISON BETWEEN ENTERIC-COATED MYCOPHENOLATE SODIUM AND MYCOPHENOLATE MOFETIL IN RENAL TRANSPLANT RECIPIENTS

10. COMPARABLE PATIENT REPORTED OUTCOMES WITH INITIALLY INTENSIFIED DOSING VERSUS STANDARD DOSING OF ENTERIC-COATED MYCOPHENOLATE SODIUM (EC-MPS) IN DE NOVO RENAL TRANSPLANT RECIPIENTS

12. IMPROVED RENAL FUNCTION OF AN EVEROLIMUS/ENTERIC-COATED MYCOPHENOLATE SODIUM REGIMEN AFTER CALCINEURIN INHIBITOR WITHDRAWAL IN DE NOVO RENAL TRANSPLANT PATIENTS: 2 YEARS FOLLOW-UP OF THE ZEUS TRIAL

13. INTENSIFIED DOSE OF ENTERIC-COATED MYCOPHENOLATE SODIUM (EC-MPS) FOR 6 WEEKS, IN COMBINATION WITH ANTI-IL2R INDUCTION, CYCLOSPORINE MICRO-EMULSION (CSA-ME) WITH OR WITHOUT STEROIDS, IN ADULT DE NOVO LOW IMMUNOLOGICAL RISK KIDNEY TRANSPLANT RECIPIENTS: FINAL EFFICACY AND SAFETY RESULTS OF A PROSPECTIVE MULTICENTER RANDOMIZED OPEN-LABEL STUDY: DOMINOS STUDY

14. PHARMOCOKINETICS OF MYCOPHENOLATE MOFETIL AND ENTERIC-COATED MYCOPHENOLATE SODIUM IN CALCINEURININHIBITOR-FREE TREATED RENAL TRANSPLANTAT PATIENTS

15. AN INTENSIFIED DOSING OF ENTERIC-COATED MYCOPHENOLATE SODIUM IN RENAL TRANSPLANT PATIENTS RESULTS IN IMPROVED EFFICACY WITHOUT COMPROMISING SAFETY: 1 YEAR FOLLOW-UP RESULTS

Catalog

Books, media, physical & digital resources